Saltar al contenido
Merck

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Blood (2014-05-14)
Ryan Flynn, Jing Du, Rachelle G Veenstra, Dawn K Reichenbach, Angela Panoskaltsis-Mortari, Patricia A Taylor, Gordon J Freeman, Jonathan S Serody, William J Murphy, David H Munn, Stefanie Sarantopoulos, Leo Luznik, Ivan Maillard, John Koreth, Corey Cutler, Robert J Soiffer, Joseph H Antin, Jerome Ritz, Jason A Dubovsky, John C Byrd, Kelli P MacDonald, Geoff R Hill, Bruce R Blazar
RESUMEN

Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Having shown that germinal center (GC) formation and immunoglobulin deposition are required for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine model, we hypothesized that T follicular helper (Tfh) cells are necessary for cGVHD by supporting GC formation and maintenance. We show that increased frequency of Tfh cells correlated with increased GC B cells, cGVHD, and BOS. Although administering a highly depletionary anti-CD20 monoclonal antibody (mAb) to mice with established cGVHD resulted in peripheral B-cell depletion, B cells remained in the lung, and BOS was not reversed. BOS could be treated by eliminating production of interleukin-21 (IL-21) by donor T cells or IL-21 receptor (IL-21R) signaling of donor B cells. Development of BOS was dependent upon T cells expressing the chemokine receptor CXCR5 to facilitate T-cell trafficking to secondary lymphoid organ follicles. Blocking mAbs for IL-21/IL-21R, inducible T-cell costimulator (ICOS)/ICOS ligand, and CD40L/CD40 hindered GC formation and cGVHD. These data provide novel insights into cGVHD pathogenesis, indicate a role for Tfh cells in these processes, and suggest a new line of therapy using mAbs targeting Tfh cells to reverse cGVHD.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Acetona, ACS reagent, ≥99.5%
Sigma-Aldrich
Acetona, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Acetona, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
Acetona, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
Acetona, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
Acetona, suitable for HPLC, ≥99.8%
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
Acetona, ACS reagent, ≥99.5%
Sigma-Aldrich
Fluorescein isothiocyanate isomer I, suitable for protein labeling, ≥90% (HPLC), powder
USP
Acetona, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Acetona, histological grade, ≥99.5%
Sigma-Aldrich
Acetona, puriss., meets analytical specification of Ph. Eur., BP, NF, ≥99% (GC)
Sigma-Aldrich
Acetona, natural, ≥97%
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, ≥90% (HPLC)
Sigma-Aldrich
Acetona, ≥99%, meets FCC analytical specifications
Sigma-Aldrich
Fluorescein isothiocyanate isomer I, ≥97.5% (HPLC)
Supelco
Acetona, analytical standard
Sigma-Aldrich
Fluorescein isothiocyanate isomer I, ≥97.5% (HPLC)
Supelco
Acetona, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetona, suitable for HPLC, ≥99.9%